**
In a significant update regarding donor safety, Grifols, the private plasma collection company, has revised its reports on serious injuries and fatalities linked to its operations in Canada. The company now states that there have been only six incidents—three of which were fatalities—since 2018, a stark reduction from the previously reported 25. This revision follows a thorough review of past regulatory submissions to Health Canada, which has accepted Grifols’s updated figures.
Revised Incident Figures
Grifols, headquartered in Barcelona, operates 17 plasma donation centres across six Canadian provinces, compensating donors for their plasma, a key component in treatments for various medical conditions, particularly those affecting the immune system. The company’s reassessment of past incident reports comes at a critical time, as it has temporarily halted collection activities since 14 August amid ongoing investigations from Health Canada into its clinics.
The firm indicated that many of the previously reported incidents did not align with the official definition of a “serious adverse reaction” as per federal guidelines. Health Canada defines such reactions as unexpected responses resulting in severe consequences, including hospitalisation, significant disability, life-threatening conditions, or death. Under these regulations, plasma collectors are mandated to report any serious reactions within a specified timeframe, with immediate notification required in the event of a donor’s death.
Health Canada’s Investigations
Recent scrutiny of Grifols intensified following the deaths of two donors in Winnipeg and alarming revelations from Health Canada inspectors. Concerns were raised regarding staff responses to alarms on donation machines and the clearance of certain donors with potential health risks. In June, Health Canada disclosed that it had recorded a total of 27 serious adverse reactions since 2018, with 25 attributed to Grifols or its predecessor companies, Prometic Plasma Resources and Canadian Plasma Resources.
Despite the ongoing investigations, Grifols maintains that the revised total of serious incidents stands at six. The incidents include one at Prometic’s Winnipeg clinic in 2018, another in 2021, and three more at Canadian Plasma Resources facilities in Saskatoon and Winnipeg occurring between 2023 and 2026.
Legal Actions and Community Concerns
The company faces legal challenges as well, including a lawsuit from a Manitoba man who claims he suffered an acute kidney injury following a donation at the Taylor Avenue location in 2023. Grifols asserts that donors are informed of the inherent risks associated with the donation process, and the case is still pending in court.
In a tragic detail, the death of 22-year-old university student Rodiyat Alabede in 2025 has raised serious questions about the safety protocols in place at Grifols. It was reported that alarms on her donation machine went off multiple times in the 45 minutes leading up to her cardiac distress, yet she was pronounced dead shortly after arriving at the hospital. Health Canada, however, has clarified that there was “no linkage” between her death and the donation process.
The Bigger Picture
Grifols’s revision of its serious adverse reaction reports and the subsequent acceptance by Health Canada highlight the vital importance of accurate reporting and the need for stringent oversight in the plasma collection industry. Despite the company’s assertions, the safety of donors continues to be a pressing concern, especially in light of recent fatalities and ongoing investigations.
Why it Matters
The revision of incident reports by Grifols is a crucial development in the ongoing discourse surrounding donor safety in Canada. As plasma collection becomes an increasingly integral part of medical treatment, understanding the risks and ensuring robust safety measures is essential. The revelations not only impact public trust in Grifols but also raise broader questions about regulatory oversight and the responsibility of plasma collectors to safeguard the health of their donors. As investigations continue, the implications for the industry and for donor safety standards remain profound.
